InnoPharma Inc. Appoints Deborah DuFresne as Vice President, Strategic Portfolio Selection & Management

InnoPharma Inc. Appoints Deborah DuFresne as Vice President, Strategic Portfolio Selection & Management

PISCATAWAY, N.J., Aug. 5, 2013 (GLOBE NEWSWIRE) -- InnoPharma, Inc. today announced the appointment of Deborah DuFresne to the role of Vice President, Strategic Portfolio Selection & Management. Ms. DuFresne will be responsible for leading InnoPharma's product selection process and the management of its portfolio. Ms. DuFresne has over 10 years of extensive experience in portfolio management, marketing, product launches, business development and strategic planning with pharmaceutical companies.

Commenting on the appointment, Navneet Puri, Ph.D., president & CEO of InnoPharma, stated, "Deborah's broad generic and specialty pharmaceutical experience and extensive product knowledge will be vital to InnoPharma as we seek to enhance our portfolio in a strategic manner. We look forward to working with Deborah as we continue to build our business and execute on our goals."

Prior to joining InnoPharma, Ms. DuFresne was Sr. Director, Project Management, Product Identification & Development at Impax Laboratories, where she was responsible for identifying new products, creating strategies for new product filings and managing the products from development to launch. Previously, Ms. DuFresne held the positions of Vice-President, Business Development at Fera Pharmaceuticals, Director of Portfolio & Project Management, Commercial Operations at Sandoz, and Sr. Product manager at Apotex. Ms. DuFresne received Bachelor of Science degrees in Biology and Chemical Engineering from The Ohio State University.

About InnoPharma, Inc.

InnoPharma is a sterile product development company, focused on developing complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. The Company has a broad portfolio of products under development, with formulations including solutions, suspension, lyophilized, emulsions, liposomes, micelles and lipid complexes. InnoPharma's pipeline includes small molecules with solubility and stability challenges, as well as difficult to produce and characterize polypeptides and carbohydrates. The Company has a comprehensive infrastructure for the development of its products in its state of the art R&D facilities in New Jersey, with the capability to handle potent and cytotoxic molecules. More information can be found at

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, some of which are outside management's control, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. InnoPharma, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

John C. Deighan, CFO
InnoPharma, Inc.
(732) 885-2939